However, researchers haven't tested this unofficial use of Wegovy to the same rigorous standards as the clinical dosing schedule, and it may not be safe
"I'm not even sure everyone can trace back where the drugs are being made," he says
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
This is usually the abdomen
All FDA-approved GLP-1 medications carry important safety information, including contraindications for patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
In phase 2 trials, discontinuation rates due to side effects ranged between 510% , which is considered acceptable for this drug class
